KD Pharma completes acquisition of dsm-firmenich’s Marine Lipids business

By Stephen Daniells

- Last updated on GMT

© Betsie Van der Meer / Getty Images
© Betsie Van der Meer / Getty Images
The KD Pharma Group has completed the acquisition of dsm-firmenich's Marine Lipids business after receiving all customer regulatory approvals. The transaction positions KD Pharma as the largest omega-3 manufacturer in the world.

Announced earlier this summer​, the deal includes dsm-firmenich's Marine Lipids omega-3 fish oil business for the food and beverage, dietary supplement and pharmaceutical markets, as well as the MEG-3 brand and production facilities in Piura, Peru and Mulgrave, Canada. In return, dsm-firmenich has received a minority stake in the enlarged KD group.

“This is a historic day for our company,” said Oscar Groet, CEO of KD Pharma Group. “We are excited about the new opportunities that lie ahead of us, which will allow us to better advance our mission of creating innovative health solutions that help people live better lives. We now have a leadership position throughout the value chain from refined oils to pharmaceutical APIs to softgel capsule manufacturing.

“We are committed to ensuring that our customers from both businesses have a seamless experience as we integrate the acquisition and promise they will receive the highest levels of service and market-leading quality.”

Building a portfolio

The deal expands KD Pharma Group‘s lipids CDMO business and will create a “well-equipped market player in Marine Lipids by combining the best of the two companies and respective expertise, with the scale of dsm-firmenich’s Piura and Mulgrave sites and the high concentration capability of the KD Pharma Group company”, KD Pharma shared in a press release.

DSM obtained the MEG-3 fish oil business when it acquired Ocean Nutrition Canada (ONC) in 2012 for C$540 million. This followed DSM’s acquisition of Martek Biosciences Corporation’s algae platform for about $1 billion in 2011.

dsm-firmenich will continue to offer MEG-3 fish oils for the Early Life Nutrition markets as well as MEG-3 powders. In addition, dsm-firmenich’s algae business is not included in the deal.

With approximately 710 employees, the expanded KD Pharma Group now has seven manufacturing facilities in the UK, Norway, Germany, Canada, Peru and the United States, and benefits from a wider range of products and customization capabilities.

                                                                                                                                       

Related products

Comprehensive Nutritional Lipid Solutions

Comprehensive Nutritional Lipid Solutions

Content provided by INNOBIO Corporation Limited | 24-Sep-2024 | White Paper

INNOBIO specializes in high-quality DurOmega® functional lipid products, emphasizing enhanced fatty acid quality and application performance.

Harness the power of algae for omega-3 innovation

Harness the power of algae for omega-3 innovation

Content provided by dsm-firmenich | 08-May-2024 | Insight Guide

Algal-sourced omega-3s have limitless potential, able to scale to meet the needs of our planet’s population with twice the potency – naturally – and all...

Nutritional Solutions for Women's Health

Nutritional Solutions for Women's Health

Content provided by INNOBIO Corporation Limited | 04-Oct-2023 | White Paper

INNOBIO provides innovative solutions for women to overcome a variety of health challenges throughout the life cycle, from emotional health, PMS management,...

Omega-3:Nutrition and Application Insight

Omega-3:Nutrition and Application Insight

Content provided by Cabio Biotech (Wuhan) Co., Ltd | 31-Jul-2023 | White Paper

Omega-3 long-chain polyunsaturated fatty acids (PUFAs) have numerous positive health benefits and are among the most extensively studied micronutrients....

Related suppliers

Follow us

Products

View more

Webinars